RE:It takes money to advance oncology R&D I have no official proof that a pp is in the making but yesterday's sudden drop had all the hallmarks of one. If so, it's quite possible that they would have a base of new profile of investors (those that can move us higher). They probably received interest from ASCO-GU, etc ...
At this point in time, with what's coming up, with now having reached the minimum threshold of data required by the FDA, priorizing the visibility on the US would make total sense. And not having to rely on retail investors would be quite positive and would signal good things to come honestly for all of us.
We'll see.
____________
ScienceFirst - (3/7/2023 8:29:32 AM)
It takes money to advance oncology R&D
The pp only means that they need/want to advance milestones (Rutherrin, GBM, NSCLC, NML, additional CSS, etc ...) before NMIBC FDA decision is announced and my take is that Breakthrough designation has not yet been been submitted but that it will by end of Q1 as they alluded that they were awaiting on whether more patients (we had 6 more coming up in a very short timeframe after p#26) on potentially guidance from the FDA or have been waiting for urologists reports. No matter what, they know where they're heading. The next few months will confirm these advances.
Remember that for GBM and NSCLC, we must hear about MSAB nominations. That would be THE signal that we have KOL experts that back the potential of our ACT platform in these 2 complex and challenging indications that are worth B$$$.